Archive · 5 Jun 2025
Dr. Reddy's Shares Jump on Cancer Drug Biosimilar Deal
Dr. Reddy's Laboratories, a medicine maker, is teaming up with Alvotech to create a copy of a cancer drug called Keytruda.
This is good news, and it made the company's stock price go up.
The drug will be used to treat different types of cancer.
Dr. Reddy's and Alvotech will work together to develop, manufacture, and sell the medicine globally.
Investors see this as a smart move to grow the company in the biosimilar market, and analysts are optimistic despite the expected competition.
Dr. Reddy's shares increased by over 3% on Thursday, June 5.
The rise followed the announcement of a partnership with Alvotech.
The partnership is for a biosimilar version of the cancer drug Keytruda.
Dr. Reddy's and Alvotech will share development and commercialization responsibilities.
Analysts view the move as a strategic bet for long-term growth.
- Who
- Dr. Reddy’s Laboratories, Alvotech, and Merck.
- What
- Dr. Reddy’s Laboratories shares rose after announcing a partnership with Alvotech to develop a biosimilar of Keytruda, a cancer treatment drug.
- When
- June 5, 2024
- Where
- Global markets
- Why
- The collaboration with Alvotech and the potential of the Keytruda biosimilar boosted investor interest.
- Company
- Dr. Reddy’s Laboratories
- Partner
- Alvotech
- Drug Target
- Keytruda (pembrolizumab)
- Drug Purpose
- Cancer Treatment
- Market
- Global
- Share Growth (Past Month)
- 10.5%
- Share Price (at 1:03 pm)
- ₹1,294.55
